8-K Announcements
6Material company update
May 28, 2026·SEC
Material company update
May 27, 2026·SEC
Material company update
May 19, 2026·SEC
Immunic, Inc.(IMUX)Earnings, Financials & Key Ratios
IMUX•NASDAQ
$15.36
Price updated Jul 7, 2026
AboutImmunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$103M-5.3%
- Net Income-$97M+3.3%
- EPS (Diluted)-6.24+37.6%
- ROE-1653.15%-289.5%
IMUX Price & Volume
Immunic, Inc. (IMUX) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Drive Severe Capital Erosion
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
Key Thesis Takeaways
- Immunic remains a high-risk, clinical-stage biotechnology firm whose valuation is entirely dependent on the successful execution of its Phase 3 ENSURE trials.
- The company faces a precarious financial outlook characterized by persistent quarterly operating losses, which reached $33.2 million in 2026Q1, and a lack of revenue to offset its heavy R&D expenditure.
- Investors should monitor the company's ability to secure non-dilutive financing, as the current cash position and negative equity status suggest an imminent need for capital to maintain operational continuity.
Verdict Logic
the company's liquidity buffer is nearing a critical threshold with only $15.5 million in cash reported as of 2025Q4, necessitating potentially dilutive financing to sustain operations.
IMUX Growth Metrics
Immunic, Inc. (IMUX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-8.19%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM38.98%
Return on Capital
10 Years-284.72%
5 Years-481.76%
3 Years-748.78%
Last Year-1702.45%
IMUX Recent Earnings
Immunic, Inc. (IMUX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$1.08-52.1%
$0.71
Rev
—
—
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$1.20-33.3%
$0.90
Rev
—
—
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$0.13+27.8%
$0.18
Rev
—
—
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.20-11.1%
$0.18
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $1.08vs $0.71-52.1% | — |
| Q1 2026 | Feb 26, 2026 | $1.20vs $0.90-33.3% | — |
| Q4 2025 | Nov 13, 2025 | $0.13vs $0.18+27.8% | — |
| Q3 2025 | Aug 7, 2025 | $0.20vs $0.18-11.1% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Immunic, Inc. (IMUX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $15.36 | $151.58M | -2.46 | — | — | -1653.15% | — | |
| $27.67 | $3.46B | -212.85 | 91.34% | -0.57% | -1.41% | — | |
| $6.39 | $377.7M | -1.71 | 8.72% | -109.99% | -61.41% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $40.51 | $3.56B | -31.65 | 3024.43% | -62.17% | -13.96% | — |
Compare IMUX vs Peers
Immunic, Inc. (IMUX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMUX SEC Filings & Documents
Immunic, Inc. (IMUX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when IMUX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IMUX Frequently Asked Questions
Immunic, Inc. (IMUX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is IMUX profitable?
Immunic, Inc. (IMUX) reported a net loss of $104.3M for fiscal year 2025.
Dividend & Returns
What is IMUX's return on equity?
Immunic, Inc. (IMUX) has a return on equity (ROE) of -1653.1%. Negative ROE indicates the company is unprofitable.
What is Immunic, Inc.'s free cash flow?
Immunic, Inc. (IMUX) had negative free cash flow of $81.4M in fiscal year 2025, likely due to heavy capital investments.